A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity

References

• Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59(2 Suppl):21-6; PMID:15142631; http://dx.doi.org/10.1016/j.ijrobp.2003.11.041
   PubMed Web of Science ®Google Scholar
• Lee CC, Shiao HY, Wang WC, Hsieh HP. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opin Investig Drugs 2014; 23(10):1333-48; PMID:24921970; http://dx.doi.org/10.1517/13543784
   PubMed Web of Science ®Google Scholar
• Chen C, Zhang Y, Zhang Y, Li J, Tsao SW, Zhang MY. Superior antitumor activity of a novel antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor, Mol Cancer Ther 2014 Jan; 13 (1):90-100; PMID:24227890; http://dx.doi.org/10.1158/1535-7163
   PubMed Web of Science ®Google Scholar
• Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007; 117(8):2051-8; PMID:17671639; http:dx.doi.org/10.1172/JCI32278
   PubMed Web of Science ®Google Scholar
• Luca T, Barresi V, Privitera G, Musso N, Caruso M, Condorelli DF, Castorina S. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif 2014; 47(5):435-47; PMID:25131935; http://dx.doi.org/10.1111/cpr.12125
   PubMed Web of Science ®Google Scholar
• Yarden Y, Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor, Biochemistry 1987; 26 (5):1443-51; PMID:3494473
   PubMed Web of Science ®Google Scholar
• Batzer AG, Rotin D, Ureña JM, Skolnik EY, Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 1994 Aug; 14(8):5192-201; PMID:7518560
   PubMed Web of Science ®Google Scholar
• Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; 1:2005.0010; PMID:16729045; http:dx.doi.org/10.1038/msb4100014
   PubMed Web of Science ®Google Scholar
• Larsen AK, Ouaret D, El Ouadrani K, Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 2011 Jul; 131(1):80-90; PMID:21439312; http://dx.doi.org/10.1016/j.pharmthera.2011.03.012
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006 May; 7(5):359-71; PMID:16633338; http://dx.doi.org/10.1038/nrm1911
   PubMed Web of Science ®Google Scholar
• Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta 2010 Aug; 1806(1):108-21; PMID:20462514; http://dx.doi.org/10.1016/j.bbcan.2010.04.004
   PubMed Web of Science ®Google Scholar
• Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 2004 Oct; 46(1):11-9; PMID:15364128; http://dx.doi.org/10.1016/j.lungcan.2004.03.006
   PubMed Web of Science ®Google Scholar
• Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nör JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 2010 Mar; 17(3):499-512; PMID:19834490; http://dx.doi.org/10.1038/cdd.2009.152
   PubMed Web of Science ®Google Scholar
• Lamalice L, Houle F, Jourdan G, Huot J. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 2004 Jan 15; 23(2):434-45; PMID:14724572; http;//dx.doi.org/10.1038/sj.onc.1207034
   PubMed Web of Science ®Google Scholar
• Dougher M, Terman BI. Autophosphorylation of VEGFR2 in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 1999 Feb 25; 18(8):1619-27; PMID:10102632
   PubMed Web of Science ®Google Scholar
• Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013 Feb; 273(2):114-27; PMID:23216836; http://dx.doi.org/10.1111/joim.12019
   PubMed Web of Science ®Google Scholar
• Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006 Jun 19; 94(12):1823-32; PMID:16773076
   PubMed Web of Science ®Google Scholar
• Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005 May 10; 23(14):3243-56; PMID:15886312; http://dx.doi.org/10.1200/JCO.2005.18.853
   PubMed Web of Science ®Google Scholar
• Markman M. Antiangiogenic drugs in ovarian cancer. Expert Opin Pharmacother 2009 Oct; 10(14):2269-77; PMID:19671017; http://dx.doi.org/10.1517/14656560903120907
   PubMed Web of Science ®Google Scholar
• Kösem M, Tuncer I, Kotan C, Ibiloğlu I, Oztürk M, Türkdoğan MK. Significance of VEGF and microvascular density in gastric carcinoma. Hepatogastroenterology 2009 Jul-Aug; 56(93):1236-40; PMID:19760978
   PubMed Web of Science ®Google Scholar
• Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer 2014 Oct 24; 13:242; PMID:25344208; http://dx.doi.org/10.1186/1476-4598-13-242
   PubMed Web of Science ®Google Scholar
• Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin Cancer Res 2014 Jul 15; 20(14):3775-86; PMID:24812410; http://dx.doi.org/10.1158/1078-0432.CCR-13-2181
   PubMed Web of Science ®Google Scholar
• Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P. Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. Mol Cancer Ther 2013 Dec; 12(12):2909-16; PMID:24130056; http://dx.doi.org/10.1158/1535-7163.MCT-13-0547
   PubMed Web of Science ®Google Scholar
• Xie W, Li D, Zhang J, Li Z, Acheampong DO, He Y, Wang Y, Chen Z, Wang M. Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2. Cancer Immunol Immunother 2014 Sep; 63(9):877-88; PMID:24893856; http://dx.doi.org/10.1007/s00262-014-1560-9
   PubMed Web of Science ®Google Scholar
• McMellen ME, Wakeman D, Erwin CR, Guo J, Warner BW. Epidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection. Surgery 2010 Aug; 148(2):364-70; PMID:20471049; http://dx.doi.org/10.1016/j.surg.2010.03.020
   PubMed Web of Science ®Google Scholar
• Cho YR1, Choi SW, Seo DW. The in vitro antitumor activity of Siegesbeckia glabrescens against ovarian cancer through suppression of receptor tyrosine kinase expression and the signaling pathways. Oncol Rep 2013 Jul; 30(1):221-6; PMID:23673404; http://dx.doi.org/10.3892/or.2013.2468
   PubMed Web of Science ®Google Scholar
• Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE, Hicklin DJ. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006 Apr 1; 12(7 Pt 1):2197-207; PMID:16609035; http://dx.doi.org/10.1158/1078-0432.CCR-05-1682
   PubMed Web of Science ®Google Scholar
• Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009 May 15; 15(10):3484-94; PMID:19447865; http://dx.doi.org/10.1158/1078-0432.CCR-08-2904
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010 Feb 20; 28(6):1075-83; PMID:20085938; http://dx.doi.org/10.1200/JCO.2009.25.3641
   PubMed Web of Science ®Google Scholar
• Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007 Apr; 7(4):295-308; PMID:17384584; http://dx.doi.org/10.1038/nrc2109
   PubMed Web of Science ®Google Scholar
• De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012 Apr; 16 Suppl 2:S17-27; PMID:22443084; http://dx.doi.org/10.1517/14728222.2011.639361
   PubMed Web of Science ®Google Scholar
• Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010 Jul 1; 16(13):3329-34; PMID:20472680; http://dx.doi.org/10.1158/1078-0432.CCR-09-3064
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011 Jan 18; 19(1):58-71; PMID:21215704; http://dx.doi.org/10.1016/j.ccr.2010.10.031
   PubMed Web of Science ®Google Scholar
• Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action. Angiogenesis 2010 Mar; 13(1):1-14; PMID:20012482; http://dx.doi.org/10.1007/s10456-009-9160-6
   PubMed Web of Science ®Google Scholar
• Gelfand MV, Hagan N, Tata A, Oh WJ, Lacoste B, Kang KT, Kopycinska J, Bischoff J, Wang JH, Gu C. Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding. Elife 2014 Sep 22; 3:e03720; PMID:25244320; http://dx.doi.org/10.7554/eLife.03720
   PubMed Web of Science ®Google Scholar
• Ohba T, Cates JM, Cole HA, Slosky DA, Haro H, Ando T, Schwartz HS, Schoenecker JG. Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma. Mol Cancer Res 2014 Aug; 12(8):1100-11; PMID:24759089, http://dx.doi.org/10.1158/1541-7786.MCR-14-0037
   PubMed Web of Science ®Google Scholar
• Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O, Majumdar AP. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 2005 Mar; 4(3):435-42; PMID:15767552; http:dx.doi.org/10.1158/1535-7163.MCT-04-0280
   PubMed Web of Science ®Google Scholar
• Tuna M, Chavez-Reyes A, Tari AM. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene 2005 Feb 24; 24(9):1648-52; PMID:15674342; http;dx.doi.org/10.1038/sj.onc.1208345
   PubMed Web of Science ®Google Scholar
• Faltus T, Yuan J, Zimmer B, Krämer A, Loibl S, Kaufmann M, Strebhardt K. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004 Nov-Dec; 6(6):786-95; PMID:15720805; http://dx.doi.org/10.1593/neo.04313
   PubMed Web of Science ®Google Scholar
• Liu K, Chen H, You Q, Shi H, Wang Z. The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell. Mol Cell Biochem 2014 Jan; 386(1-2):117-24; PMID:24158524; http://dx.doi.org/10.1007/s11010-013-1850-0
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003 Apr; 13(2):159-67; PMID:12654259; http://dx.doi.org/10.1016/S1044-579X(02)00133-5
   PubMed Web of Science ®Google Scholar
• Xuan ZX, Li LN, Zhang Q, Xu CW, Yang DX, Yuan Y, An YH, Wang SS, Li XW, Yuan SJ. Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth. Int J Oncol 2014 Dec; 45(6):2411-20; PMID:25269419; http://dx.doi.org/10.3892/ijo.2014.2690
   PubMed Web of Science ®Google Scholar
• Hsu YH, Wei CC, Shieh DB, Chan CH, Chang MS.Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth. Mol Cancer Res 2012 Nov; 10(11):1430-9; PMID:23002091; http://dx.doi.org/10.1158/1541-7786.MCR-12-0276
   PubMed Web of Science ®Google Scholar